Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Egypt / NCT07263282
Starting soon Observational

LA Strain in Predicting Early Complication in STEMI After PPCI

NCT07263282 · tracked via the Priya Life Science Egypt tracker
Sponsor
Assiut University
Phase
Observational
Started
2025-12-01
Last updated
2025-12-12

Condition(s) studied

ST Elevation (STEMI) Myocardial Infarction

Investigational drug(s) / intervention(s)

2D echocardiography

2D echocardiography: LA strain by 2D echocardiographic speckle tracking analysis

Study summary

The goal of this observational study To evaluate the predictive value of left atrial strain for in-hospital outcomes in patients with ST-segment elevation myocardial infarction undergoing PPCI. The main questions it aims to answer are:

Is low parameters of left atrial strain associated early complication ? What is the correlation between LA strain parameters and conventional echocardiographic indices of left ventricular systolic and diastolic function ? Is there more affection to LA strain in certain territory over the others ? What is the correlation between LA strain and LA volume index across infarct territories ? Does LA strain Correlate with TAPSE and PASP to evaluate right-heart interactions ?

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Adults aged ≥18 years. * Diagnosed with ST-segment elevation myocardial infarction (STEMI) according to current ESC/AHA criteria * Underwent successful primary percutaneous coronary intervention (PPCI) within 12 hours of symptom onset. * Sinus rhythm on admission . * Trans thoracic echocardiography (TTE) performed within 48 hours of admission with adequate image quality for speckle-tracking analysis. Exclusion Criteria: * Previous myocardial infarction or prior PCI/CABG. * Patients known to have atrial fibrillation or other sustained supraventricular arrhythmias. * Significant valvular heart disease (severe stenosis or regurgitation). * Congenital heart disease or cardiomyopathy (hypertrophic, dilated, restrictive). * Poor echocardiographic window preventing LA strain analysis . * Mechanical complications (e.g., papillary muscle rupture, VSD, free wall rupture). * Prior cardiac surgery or known structural lesions that preventing reliable LA measurement. * patient presenting with killip class III or IV from the start

Primary outcome measure(s)

  • the predictive value of left atrial strain for detecting incidence of in-hospital outcomes in patients with ST-segment elevation myocardial infarction undergoing primary PCI. — up to one week
    To evaluate the predictive value of left atrial strain for hospitalized patients with ST-segment elevation myocardial infarction undergoing primary PCI as regarding * All-cause in-hospital mortality * New/worsening heart failure requiring IV therapy or ICU care * Cardiogenic shock (requiring inotropes or mechanical support) * Sustained ventricular arrhythmia (VT/VF)

Trial sites (1)

FacilityCityRegionStatus
Assiut university Asyut Egypt

More Assiut University trials in Egypt

Combined Hystroscopic and Laparoscopic Repair of CS Scar Disorder Recruiting
The Outcome of Inserting Intercostal Tube or Pleurodesis for Malignant Pleural Effusion Starting soon
Maternal Iron Deficiency and/or Iron Deficiency Anemia to Neonatal Hemoglobin Concentration and Iron Stores Starting soon
Real-Time (TRUS) Guidance in Endoscopic Treatment of BPH Starting soon
Intraoperative Lidocaine Infusion Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07263282 on ClinicalTrials.gov ↗ ← All trials in Egypt